[Federal Register Volume 80, Number 250 (Wednesday, December 30, 2015)]
[Notices]
[Pages 81555-81556]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32879]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute, Technology Transfer 
Center on or before January 29, 2016 will be considered.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD, 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below may be

[[Page 81556]]

obtained by contacting: Attn. Invention Development and Marketing Unit, 
Technology Transfer Center, National Cancer Institute, 9609 Medical 
Center Drive, Mail Stop 9702, Rockville, MD, 20850-9702, Tel. 240-276-
5515 or email [email protected]. A signed Confidential 
Disclosure Agreement may be required to receive copies of the patent 
applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: A Novel Fully-Human Anti-CD30 Chimeric Antigen 
Receptor for Treatment of CD30+ Lymphoma.
    Description of Technology: Chimeric antigen receptors (CARs) are 
hybrid proteins that consist of two major components: A targeting 
domain and a signaling domain. The targeting domain allows T cells 
which express the CAR to selectively recognize and bind to diseased 
cells that express a particular protein. Once the diseased cell is 
bound by the targeting domain of the CAR, the signaling domain of the 
CAR activates the T cell, thereby allowing it to kill the diseased 
cell. This is a promising new therapeutic approach known as adoptive 
cell therapy (ACT).
    Researchers at the National Cancer Institute's Experimental 
Transplantation and Immunology Branch developed a CAR that recognizes 
human tumor necrosis factor receptor superfamily member 8 (TNFRSF8, 
also known as CD30). The expression of CD30 is deregulated in a variety 
of human cancers, including many lymphomas. By creating a CAR that 
recognizes CD30, it may be possible to treat these cancers using 
adoptive cell therapy.

Potential Commercial Applications

    --Treatment of human cancers associated with expression of CD30 or 
variants thereof
    --Specific cancers include: Non-Hodgkins Lymphomas, Hodgkin's 
Lymphomas, several solid malignancies

Value Proposition

    --Human components are less likely to cause adverse or neutralizing 
immune response in patients
    --Targeted therapies decrease non-specific killing of healthy cells 
and tissues, resulting in fewer off-target side-effects and healthier 
patients

Development Stage

In vivo/Lead Validation.

Inventor(s)

Jim N. Kochenderfer, M.D. (NCI).

Intellectual Property

HHS Reference No. E-001-2016/0-US-01
US Provisional Application 62/241,896 (HHS Reference No. E-001-2016/0-
US-01) filed October 15, 2015 entitled ``A Novel Fully-Human Anti-CD30 
Chimeric Antigen Receptor for Treatment of CD30+ Lymphoma''
    Licensing Opportunity: Researchers at the NCI seek licensees for a 
chimeric antigen receptor (CAR) that recognizes human tumor necrosis 
factor receptor superfamily member 8 (TNFRSF8, also known as CD30) for 
use as a cancer therapeutic.

Contact Information

    Requests for copies of the patent application or inquiries about 
licensing and/or research collaboration and co-development 
opportunities should be sent to John D. Hewes. Ph.D., email: 
[email protected].

    Dated: December 22, 2015.
Thomas M. Stackhouse,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2015-32879 Filed 12-29-15; 8:45 am]
 BILLING CODE 4140-01-P